Asahi Kasei Therapeutics Corp - Company Profile
Powered by 
All the sales intelligence you need on Asahi Kasei Therapeutics Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Asahi Kasei Therapeutics Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Asahi Kasei Therapeutics Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Asahi Kasei Therapeutics Corp (Asahi Kasei Therapeutics), a subsidiary of Asahi Kasei Corp, manufactures and markets diagnostic reagents, prescription drugs, and enzymes for diagnostic reagents. Its prescription drugs are used in the treatment of osteoporosis pain, bone loss, dysuria accompanying benign prostatic hyperplasia, disseminated intravascular coagulation, proteinuria in nephrotic syndrome, nocturia and lupus nephritis, among others. Asahi Kasei Therapeutics offers assay kits for glycemic control and to detect prediabetes. The company’s pipeline products are intended for the treatment of chemotherapy-induced peripheral neuropathy, osteoporosis with high risk of fracture, Lupus nephritis and nephrotic syndrome, and severe sepsis with coagulopathy, among others. The company has facilities in Shizuoka, and Nagoya, Japan. Geographically, the company has business operations in the US, China and Japan. Asahi Kasei Therapeutics is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
1-1-2 Yurakucho, Hibiya Mitsui Tower, Chiyoda, Tokyo, 100-0006
Website
www.asahi-kasei.co.jp/pharma
Telephone
81 3 66993600
Industry
Pharmaceuticals and Healthcare
Asahi Kasei Therapeutics Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Prescription Drugs | Bredinin |
| Enzymes for Diagnostic Reagents | Elcitonin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In September, the company signed an agreement to sell its diagnostics business and other elements to Nagase & Co., Ltd. |
| 2023 | New Products/Services | In August, the company licensed on the National Health Index for drug price standard and marketing of Empaveli for subcutaneous injection 1080 mg in Japan. |
| 2023 | Contracts/Agreements | In August, the company entered into a new agreement with AGC Biologics to produce clinical drug substance for antibody-based therapies. |
Competitor Comparison
| Key Parameters | Asahi Kasei Therapeutics Corp | Otsuka Pharmaceutical Co Ltd | Rohto Pharmaceutical Co Ltd | Dong-A Socio Holdings Co Ltd | Denka Seiken Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | South Korea | Japan |
| City | Chiyoda | Chiyoda-Ku | Osaka-Shi | Seoul | Chuo-Ku |
| State/Province | Tokyo | Tokyo | Osaka | - | Tokyo |
| No. of Employees | - | 6,070 | 9,144 | 273 | - |
| Entity Type | Private | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yoshikazu Aoki | Chairman | Executive Board | - | - |
| Daisuke Okajima | Director; President | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer